Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 236

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study

Open access
García-Suárez, Julio, de la Cruz, Javier, Cedillo, Ángel, Llamas, Pilar, Duarte, Rafael, Jiménez-Yuste, Víctor, Hernández-Rivas, José Ángel, Gil-Manso, Rodrigo, Kwon, Mi, Sánchez-Godoy, Pedro, Martínez-Barranco, Pilar, Colás-Lahuerta, Blanca, Herrera, Pilar, Benito-Parra, Laurentino, Alegre, Adrián, Velasco, Alberto, Matilla, Arturo, Aláez-Usón, María Concepción, Martos-Martínez, Rafael, Martínez-Chamorro, Carmen, Susana-Quiroz, Keina, Del Campo, Juan Francisco, de la Fuente, Adolfo, Herráez, Regina, Pascual, Adriana, Gómez, Elvira, Pérez-Oteyza, Jaime, Ruiz, Elena, Alonso, Arancha, González-Medina, José, Martín-Buitrago, Lucía Núñez, Canales, Miguel, González-Gascón, Isabel, Vicente-Ayuso, María Carmen, Valenciano, Susana, Roa, María García, Monteliu, Pablo Estival, López-Jiménez, Javier, Escobar, Cristián Escolano, Ortiz-Martín, Javier, Diez-Martin, José Luis, Martinez-Lopez, Joaquín, the Asociación Madrileña de Hematología y Hemoterapia (AMHH), Serí-Merino, Cristina, Queiroz-Cervantes, Keina, Fernandez, Mónica Estévez, Peñalva-Moreno, María-José, Naya-Errea, Daniel, Bermejo-Martínez, Laura, Llorente-González, Laura · 2020 · Journal of Hematology & Oncology

Abstract

Background: Patients with cancer have been shown to have a higher risk of clinical severity and mortality compared to non-cancer patients with COVID-19. Patients with hematologic malignancies typically are known to have higher levels of immunosuppression and may develop more severe respiratory viral infections than patients with solid tumors. Data on COVID-19 in patients with hematologic malignancies are limited. Here we characterize disease severity and mortality and evaluate potential prognostic factors for mortality. Methods: In this population-based registry study, we collected de-identified data on clinical characteristics, treatment and outcomes in adult patients with hematologic malignancies and confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection within the Madrid region of Spain. Our case series included all patients admitted to 22 regional health service hospitals and 5 private healthcare centers between February 28 and May 25, 2020. The primary study outcome was all-cause mortality. We assessed the association between mortality and potential prognostic factors using Cox regression analyses adjusted for age, sex, comorbidities, hematologic malignancy and recent active cancer therapy. Results: Of 833 patients reported, 697 were included in the analyses. Median age was 72 years (IQR 60–79), 413 (60%) patients were male and 479 (69%) and 218 (31%) had lymphoid and myeloid malignancies, respectively. Clinical severity of COVID-19 was severe/critical in 429 (62%) patients. At data cutoff, 230 (33%) patients had died. Age ≥ 60 years (hazard ratios 3.17–10.1 vs < 50 years), > 2 comorbidities (1.41 vs ≤ 2), acute myeloid leukemia (2.22 vs non-Hodgkin lymphoma) and active antineoplastic treatment with monoclonal antibodies (2·02) were associated with increased mortality; conventional chemotherapy showed borderline significance (1.50 vs no active therapy). Conversely, Ph-negative myeloproliferative neoplasms (0.33) and active treatment with hypomethylating agents (0.47) were associated with lower mortality. Overall, 574 (82%) patients received antiviral therapy. Mortality with severe/critical COVID-19 was higher with no therapy vs any antiviral combination therapy (2.20). Conclusions: In this series of patients with hematologic malignancies and COVID-19, mortality was associated with higher age, more comorbidities, type of hematological malignancy and type of antineoplastic therapy. Further studies and long-term follow-up are required to validate these criteria for risk stratification.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13045-020-00970-7

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 236

Metadata

Authors
García-Suárez, J., de la Cruz, J., Cedillo, Á., Llamas, P., Duarte, R., Jiménez-Yuste, V., Hernández-Rivas, J. Á., Gil-Manso, R., Kwon, M., Sánchez-Godoy, P., Martínez-Barranco, P., Colás-Lahuerta, B., Herrera, P., Benito-Parra, L., Alegre, A., Velasco, A., Matilla, A., Aláez-Usón, M. C., Martos-Martínez, R., Martínez-Chamorro, C., Susana-Quiroz, K., Del Campo, J. F., de la Fuente, A., Herráez, R., Pascual, A., Gómez, E., Pérez-Oteyza, J., Ruiz, E., Alonso, A., González-Medina, J., Martín-Buitrago, L. N., Canales, M., González-Gascón, I., Vicente-Ayuso, M. C., Valenciano, S., Roa, M. G., Monteliu, P. E., López-Jiménez, J., Escobar, C. E., Ortiz-Martín, J., Diez-Martin, J. L., Martinez-Lopez, J., (AMHH), T. A. M. D. H. Y. H., Serí-Merino, C., Queiroz-Cervantes, K., Fernandez, M. E., Peñalva-Moreno, M.-J., Naya-Errea, D., Bermejo-Martínez, L., & Llorente-González, L.
Venue
Journal of Hematology & Oncology
Published
2020-10-08
Volume
13
Issue
1
Pages
133-133
ISSN
1756-8722 (ISSN-L)
OpenAlex
W3092343514
Cited by
236
References
5
FWCI
5.85
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. https://app.cochat.ai/papers/10.1186/s13045-020-00970-7
The paper
García-Suárez, J., de la Cruz, J., Cedillo, Á., Llamas, P., Duarte, R., Jiménez-Yuste, V., Hernández-Rivas, J. Á., Gil-Manso, R., Kwon, M., Sánchez-Godoy, P., Martínez-Barranco, P., Colás-Lahuerta, B., Herrera, P., Benito-Parra, L., Alegre, A., Velasco, A., Matilla, A., Aláez-Usón, M. C., Martos-Martínez, R., . . . Llorente-González, L. (2020). Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-020-00970-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.